Efficacy and safety of treatments used in differentiated thyroid cancer (DTC): A systematic review

Main Article Content

Ritesh Bisen
Lalit Thakur
Gayatri Shivsingwale

Abstract

Patients diagnosed with differentiated thyroid cancer (DTC) are offered multiple targeted therapeutics, but it is unclear which pharmaceutical therapies are most effective and safe. A systematic literature review (SLR) was performed to assess the clinical efficacy and safety of targeted therapeutics in DTC patients. A comprehensive search was performed across MEDLINE®, Embase®, and Evidence-based Medicine (EBM) Reviews databases, along with grey literature search. Eighteen studies that met the inclusion criteria were identified from 5,334 publications. Two studies assessed treatments in the DTC population, whereas 16 addressed the radioactive iodine resistant (RAIR) sub-population. In DTC patients, nintedanib led to a modest increase in progression-free survival (PFS) compared to placebo (3.71 months vs 2.86 months). Selumetinib with radioactive iodine had minimal impact on complete remission rates (40 vs. 38%) but raised concerns due to adverse events (AEs). In the RAIR sub-population, various treatments, including donafenib, lenvatinib, anlotinib, apatinib, cabozantinib, cediranib, dabrafenib+trametinib, sorafenib, pazopanib, and vandetanib, demonstrated clinical benefits, ranging from 2% (intermittent pazopanib) to 69.9% (lenvatinib). Furthermore, cabozantinib significantly improved PFS compared to placebo, with anlotinib reaching a remarkable 40.54 months. AEs, predominantly grade 1-2, have been reported across studies, with hypertension, diarrhea, and skin reactions being common. While lenvatinib was effective, it had a high AE rate of 75.9% (grade 3). Despite modest progress in the general DTC population, lenvatinib has revolutionized RAIR-DTC treatment by delivering a higher response rate and extended survival, albeit with a higher risk of AEs. Therefore, further research is needed to enhance the understanding and outcomes of both DTC and RAIR-DTC.

Metrics

Metrics Loading ...

Article Details

How to Cite
Bisen, R., Thakur, L., & Shivsingwale, G. (2024). Efficacy and safety of treatments used in differentiated thyroid cancer (DTC): A systematic review. Systematic Literature Review and Meta-Analysis Journal, 5(2), 1–19. https://doi.org/10.54480/slr-m.v5i2.72
Section
Articles

References

Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., De La Fouchardiere, C., Pacini, F., Paschke, R., & Shong, Y. K. (2014). Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet, 384(9940), 319-328. https://doi.org/10.1016/S0140-6736(14)60421-9

Brose, M. S., Panaseykin, Y., Konda, B., de La Fouchardiere, C., Hughes, B. G., Gianoukakis, A. G., Joo Park, Y., Romanov, I., Krzyzanowska, M. K., & Leboulleux, S. (2022). A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. The Journal of Clinical Endocrinology & Metabolism, 107(3), 776-787. https://doi.org/10.1210/clinem/dgab731

Brose, M. S., Robinson, B. G., Sherman, S. I., Jarzab, B., Lin, C. C., Vaisman, F., Hoff, A. O., Hitre, E., Bowles, D. W., & Sen, S. (2022). Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial. Cancer, 128(24), 4203-4212. https://doi.org/10.1002/cncr.34493

Busaidy, N. L., Konda, B., Wei, L., Wirth, L. J., Devine, C., Daniels, G. A., DeSouza, J. A., Poi, M., Seligson, N. D., & Cabanillas, M. E. (2022). Dabrafenib versus dabrafenib+ trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid, 32(10), 1184-1192. https://doi.org/10.1089/thy.2022.0115

Cabanillas, M. E., Schlumberger, M., Jarzab, B., Martins, R. G., Pacini, F., Robinson, B., McCaffrey, J. C., Shah, M. H., Bodenner, D. L., & Topliss, D. (2015). A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer, 121(16), 2749-2756. https://doi.org/10.1002/cncr.29395

Chi, Y., Gao, M., Zhang, Y., Shi, F., Cheng, Y., Guo, Z., Ge, M., Qin, J., Zhang, J., & Li, Z. (2020). Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase II trial. Annals of Oncology, 31(6), S1347. https://doi.org/10.1016/j.annonc.2020.10.259

Coca-Pelaz, A., Rodrigo, J. P., Shah, J. P., Nixon, I. J., Hartl, D. M., Robbins, K. T., Kowalski, L. P., Mäkitie, A. A., Hamoir, M., & López, F. (2023). Recurrent differentiated thyroid cancer: the current treatment options. Cancers, 15(10), 2692. https://doi.org/10.3390/cancers15102692

de la Fouchardière, C., Godbert, Y., Dalban, C., Illouz, F., Wassermann, J., Do Cao, C., Bardet, S., Zerdoud, S., Chougnet, C. N., & Zalzali, M. (2021). Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. European Journal of Cancer, 157, 153-164. https://doi.org/10.1016/j.ejca.2021.07.029

Dunlap, Q., & Davies, L. (2021). Differentiated thyroid cancer incidence. In Surgery of the Thyroid and Parathyroid Glands (pp. 174-180. e172). Elsevier. https://doi.org/10.1016/B978-0-323-66127-0.00017-X

Grimm, D. (2022). Recent advances in thyroid cancer research. International Journal of Molecular Sciences, 23(9), 4631. https://doi.org/10.3390/ijms23094631

Ho, A. L., Dedecjus, M., Wirth, L. J., Tuttle, R. M., Inabnet III, W. B., Tennvall, J., Vaisman, F., Bastholt, L., Gianoukakis, A. G., & Rodien, P. (2022). Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase III, randomized, placebo-controlled trial (ASTRA). Journal of Clinical Oncology, 40(17), 1870-1878. https://doi.org/10.1200/JCO.21.00714

Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., & Soufflet, C. (2012). Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. The lancet oncology, 13(9), 897-905. https://doi.org/10.1016/S1470-2045(12)70335-2

Lechner, M. G., Praw, S. S., & Angell, T. E. (2019). Treatment of differentiated thyroid carcinomas. Surgical Pathology Clinics, 12(4), 931-942. https://doi.org/10.1016/j.path.2019.08.003

Liao, C.-Y. (2018). Cediranib maleate with or without lenalidomide for the treatment of thyroid cancer. ClinicalTrials.gov identifier: NCT01208051, Accessed March 8, 2024. https://clinicaltrials.gov/study/NCT01208051

Lin, Y.-S., Yang, H., Ding, Y., Cheng, Y.-Z., Shi, F., Tan, J., Deng, Z.-Y., Chen, Z.-D., Wang, R.-F., & Ji, Q.-H. (2021). Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II trial. Thyroid, 31(4), 607-615. https://doi.org/10.1089/thy.2020.0235

Lin, Y., Qin, S., Li, Z., Yang, H., Fu, W., Li, S., Chen, W., Gao, Z., Miao, W., & Xu, H. (2022). Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine–refractory differentiated thyroid cancer: The REALITY randomized clinical trial. JAMA oncology, 8(2), 242-250. https://doi.org/10.1001/jamaoncol.2021.6268

Lin, Y., Yang, H., Shi, F., Yang, A., Han, X., Liu, B., Li, Z., Ji, Q., Tang, L., & Deng, Z. (2022). 1644O Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION). Annals of Oncology, 33(7), S1294. https://doi.org/10.1016/j.annonc.2022.07.1724

National Institute for Health and Care Excellence (NICE). (2015). Single Technology Appraisal (STA): User guide for company evidence submission template. (March 8, 2024). https://www.nice.org.uk/process/pmg24/chapter/clinical-effectiveness#quality-assessment-of-the-relevant-randomised-controlled-trials

NCT01876784. (2018). Evaluation of efficacy, safety of vandetanib in patients with differentiated thyroid cancer (VERIFY). ClinicalTrials.gov identifier: NCT01876784, Accessed March 8, 2024. https://clinicaltrials.gov/study/NCT01876784

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., & Brennan, S. E. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj, 372. https://doi.org/10.1016/j.ijsu.2021.105906

Robinson, B., Schlumberger, M., Sherman, S., Tahara, M., Wirth, L., Brose, M., Elisei, R., Habra, M., Dutcus, C., Zhu, J., & Newbold, K. (2015). Open-label extension phase outcomes of the Phase 3 SELECT trial of lenvatinib in patients with 131I-refractory differentiated thyroid cancer. Endocrine Reviews, 36(Supplement). https://doi.org/10.1093/edrv/36.supp.1

Schlumberger, M., Brose, M., Elisei, R., Leboulleux, S., Luster, M., Pitoia, F., & Pacini, F. (2014). Definition and management of radioactive iodine-refractory differentiated thyroid cancer. The lancet Diabetes & endocrinology, 2(5), 356-358. https://doi.org/10.1016/S2213-8587(13)70215-8

Schlumberger, M., Newbold, K., Hasan, B., Marreaud, S., Assele, S., Licitra, L. F., Schoffski, P., Leboulleux, S., Locati, L., & Godbert, Y. (2018). A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209. Journal of Clinical Oncology, 36(15). https://doi.org/10.1200/JCO.2018.36.15_suppl.6021

Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., & Hoff, A. O. (2015). Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine, 372(7), 621-630. https://doi.org/10.1056/NEJMoa1406470

Sherman, E. (2019). Sorafenib tosylate with or without everolimus in treating patients with advanced, radioactive iodine refractory hurthle cell thyroid cancer. ClinicalTrials.gov identifier: NCT02143726, Accessed March 8, 2024. https://clinicaltrials.gov/study/NCT02143726

Stewart, L. A., & Kuo, J. H. (2021). Advancements in the treatment of differentiated thyroid cancer. Therapeutic Advances in Endocrinology and Metabolism, 12, 20420188211000251. https://doi.org/10.1177/20420188211000251

Thyroid Cancer Stages. American Cancer Society. Retrieved March 8, 2024 from https://www.cancer.org/cancer/types/thyroid-cancer/detection-diagnosis-staging/staging.html

Van Den Heede, K., Tolley, N. S., Di Marco, A. N., & Palazzo, F. F. (2021). Differentiated thyroid cancer: A health economic review. Cancers, 13(9), 2253. https://doi.org/10.3390/cancers13092253

Xu, Y., Wu, D., Wu, W., Jiang, J., Xi, C., Ye, N., Wang, Y., & Xu, X. (2019). Diagnostic value of cytology, thyroglobulin, and combination of them in fine-needle aspiration of metastatic lymph nodes in patients with differentiated thyroid cancer: a systematic review and network meta-analysis. Medicine, 98(45), e17859. https://doi.org/10.1097/MD.0000000000017859

Zheng, X., Xu, Z., Ji, Q., Ge, M., Shi, F., Qin, J., Wang, F., Chen, G., Zhang, Y., & Huang, R. (2021). A randomized, phase III study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer. Clinical Cancer Research, 27(20), 5502-5509. https://doi.org/10.1158/1078-0432.CCR-21-0761